Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, BioMérieux Collaborate on NGS-based Applications for Microbiology

NEW YORK(GenomeWeb) – BioMérieux and Illumina today announced a collaboration to develop applications for microbiology sequencing technologies.

The work, to be conducted over a four-year renewable period, will combine Illumina's MiSeq next-generation sequencing system with a jointly developed pathogen genome database based on BioMérieux's culture collection containing more than 80,000 references.

The first application will be an NGS epidemiological solution to enable service labs to genotype disease agents. The application will provide "easily accessible and highly accurate information to communities and hospitals to track, prevent, contain, and stop the spread of disease agents" by delivering "a standardized report with a genomic profile of the infectious agent with sequence-level accuracy and depth of information," the partners said.

The goal of the collaboration is to arm public health and hospital microbiology labs with tools to contain an epidemic, avoid transmission of infectious agents, and improve hospital practices. Healthcare providers will be able to send the relevant isolates to a designated lab equipped with an Illumina platform. Genetic sequences will be sent securely through a cloud platform to be analyzed using the database and software developed by BioMérieux, and the lab will be able to generate a customized report for the customer.

Financial and other terms of the agreement were not disclosed.

"With this new collaboration, we will enrich our commercial offering by adding a sequencing solution dedicated to infectious diseases," BioMérieux Chairman Jean-Luc Belingard said in a statement. "Moreover, this collaboration is a first step that will enable BioMérieux to identify opportunities and fields of application that sequencing can bring to infectious disease diagnostics."

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.